 | | Vol. 12.29 – 27 July, 2021 |
| |
|
|
| Scientists demonstrated that an oncogenic mutant form of NPM1 (NPM1c) impaired mitochondrial function. NPM1c also hampered formation of PML nuclear bodies, which are regulators of mitochondrial fitness and key senescence effectors.
[Cancer Discovery] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators performed a metabolic drug screen to identify leukemic stem cell (LSC)-specific vulnerabilities and found that nicotinamide phosphoribosyltransferase inhibitors selectively killed LSCs, while sparing normal hematopoietic stem and progenitor cells.
[Cell Stem Cell] |
|
|
|
| Researchers introduced sialic-acid-binding immunoglobulin-like lectin (Siglec)-6 as a novel target for CAR T-cells in acute myeloid leukemia (AML) and found that Siglec-6 was prevalently expressed on AML cell lines and primary AML blasts, including the subpopulation of AML stem cells.
[Blood] |
|
|
|
| The authors characterized direct SARS-CoV-2-platelet interactions using in vitro studies with purified infectious virions and samples from infected patients.
[Circulation Research] |
|
|
|
| Scientists demonstrated that NAD+ metabolism enabled acute myeloid leukemia (AML) to evade apoptosis. They integrated whole-genome CRISPR screening and pan-cancer genetic dependency mapping to identify NAMPT and NMNAT1 as AML dependencies governing NAD+ biosynthesis.
[Science Advances] |
|
|
|
| Researchers identified TNFα as a key determinant of paracrine senescence and myeloid-restricted hematopoiesis and showed that its inhibition dampened inflammation, delayed disease onset and rescued hematopoietic defects in bystander cells.
[Nature Communications] |
|
|
|
| The authors found that the P2X4 receptor promoted trafficking of hematopoietic stem progenitor cells (HSPCs) in that its deficiency led to impaired chemotaxis of HSPCs in response to a stromal-derived factor 1 gradient, less effective pharmacological mobilization, and defective homing and engraftment of HSPCs after transplantation into myeloablated hosts.
[Leukemia] |
|
|
|
| Investigators used two different single-cell RNA sequencing technologies to analyze the expression of a prednisone-dependent signature, derived from an independent study, in diagnostic bone marrow and peripheral blood biopsies.
[Leukemia] |
|
|
|
| Scientists identified that guanylate-binding protein (GBP)1 and GBP2 interacted with MCL-1, the key prosurvival member of the BCL-2 family, via its BH3 domain. GBPs induced caspase-dependent apoptosis in chronic myeloid leukemia and acute myeloid leukemia cells, where the proapoptotic BCL-2 member, BAK, was an indispensable mediator.
[Oncogenesis] |
|
|
|
| The authors investigated the hypersensitivity immune response of HSCs to various viral and bacterial stimuli, and found that hypersensitivity induced no significant change in the proliferative state of HSCs.
[Stem Cell Reports] |
|
|
|
| | This Phase II open-label study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myelogenous leukemia (CML) met its coprimary end points, showing sustained nilotinib efficacy in patients with newly diagnosed or imatinib/dasatinib resistant/intolerant CML.
[Blood Advances] |
|
|
|
| Researchers conducted a Phase II, multicenter, open-label study to evaluate the safety and antileukemic activity of azacitidine monotherapy prior to hematopoietic stem cell transplantation in newly diagnosed juvenile myelomonocytic leukemia patients.
[Blood Advances] |
|
|
|
| This Phase Ib trial evaluated ficlatuzumab, a first-in-class anti-HGF antibody, in combination with cytarabine in acute myeloid leukemia (AML) patients. Among 17 evaluable patients, the overall response rate was 53%, all complete remissions.
[Blood Cancer Discovery] |
|
|
|
|
| Scientists describe how changes in bone marrow niche composition (ecosystem) and structure (remodeling) modulate activation of HSCs in situ.
[Frontiers in Cell and Developmental Biology] |
|
|
|
| The authors suggest that proteomic profiles at the early stage of chronic lymphocytic leukemia (CLL) can discriminate progressive from stable disease and that RNA splicing dysregulation underlies CLL evolution, which opens new perspectives in terms of biomarkers and therapy.
[Journal of Leukocyte Biology] |
|
|
|
| Investigators summarize emerging research on CHIP, the mechanisms underlying its important role in propagating inflammation and accelerating cardiovascular disease, and new studies detailing the role of associated risk factors and co-morbidities that increase CHIP prevalence.
[Journal of Molecular and Cellular Cardiology] |
|
|
|
|
| Magenta Therapeutics, Inc. announced that it has received a clinical hold letter from the US FDA related to its Investigational New Drug Application filed in June 2021 to initiate a Phase I/II clinical trial of MGTA-117 in patients with acute myeloid leukemia and myelodysplastic syndrome.
[Magenta Therapeutics, Inc.] |
|
|
|
| Hemab ApS, a biotechnology company developing next generation therapeutics for serious underserved bleeding and thrombosis disorders, announced the successful closing of a US $55M Series A financing.
[Hemab ApS] |
|
|
|
|
| September 23 – 30, 2021
Virtual |
|
|
|
|
|
| | Dalhousie University – Halifax, Nova Scotia, Canada |
|
|
|
| | Aarhus University – Aarhus, Denmark |
|
|
|
| | University of Wisconsin–Madison – Madison, Wisconsin, United States |
|
|
|
| | The Technical University of Munich – Munich, Germany |
|
|
|
| | The Westmead Institute for Medical Research – Sydney, Australia |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
